An antibody raised against Cystatin-C; An inhibitor of local cysteine proteases, it has an important physiological role as a regulator of this enzyme activity. The peptide plays a significant role in kidney function, cardiovascular disease (CVD), neurological conditions and is being considered as a biomarker for disease indication and prognosis.
Catalogue number crb2005651 Antibody Anti-Cystatin-C antibody Antigen Peptide KLH conjugated synthetic peptide crb1200860e Protein ID P01034 Human CST3 Aliases Cystatin-C, CST3, Cystatin-3, Gamma-trace, Neuroendocrine basic polypeptide, Post-gamma-globulin Cross-Reactivity Human Host Species Rabbit Antibody Type Polyclonal Concentration 1mg/ml Glycine (R1G), 1mg/ml Glycine (R2G) Target Cystatin-C
This peptide is a known inhibitor of cathepsin B, a cysteine protease critical in the degradation of β-amyloid. This could explain why amyloid brain disorders implicate a role for cystatin-C such as Alzheimer′s disease. A single point mutation in CST3 causes the hereditary disease cystatin-C amyloid angiopathy (HCCAA). Generalised deposits of cystatin-C amyloids accumulate on the walls of all blood vessels including within the brain leading to dementia, premature strokes, and fatal brain haemorrhage. Other mutations of CST3 have been associated with macular degeneration, where cysteine protease cathepsin s is a key regulator in retinal pigment epithelial cells.
Cystatin-C is a low molecular mass peptide produced by most human tissue and is cleared from the plasma by the kidneys, it is being explored as biomarker in numerous areas. Creatinine is being surpassed as the most appropriate kidney biomarker in the medical field by measurement of cystatin-C in serum using the glomerular filtration rate (GFR). As a biomarker cystatin-C has also been shown to predict the formation or progression of CVD. Meanwhile, for prion diseases there are no pre-mortem biomarkers available yet. However, a study found cystatin-C cerebrospinal fluid levels to be significantly raised in Creutzfeldt-Jakob patients suggesting this could be the first. The potential of this peptide as a research tool can not be understated.